Skip to main content
Funding round brings in $235M for AskBio
4/15/2019

Gene therapy developer Asklepios BioPharmaceutical gained $235 million through an investment made by Vida Ventures and TPG Capital, along with one by AskBio's board and founders. The money will be used to fund gene therapy research and development for rare genetic disorders.

Full Story: